Raymond James Sticks to Their Hold Rating for GoodRx Holdings (GDRX)

Raymond James analyst Aaron Kessler maintained a Hold rating on GoodRx Holdings (GDRXResearch Report) yesterday. The company’s shares closed last Wednesday at $51.10.

According to TipRanks.com, Kessler is a top 100 analyst with an average return of 24.6% and a 73.0% success rate. Kessler covers the Technology sector, focusing on stocks such as Jumia Technologies AG, Uber Technologies, and Alphabet Class C.

GoodRx Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $58.69, representing a 16.9% upside. In a report issued on November 9, RBC Capital also maintained a Hold rating on the stock with a $55.00 price target.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

GoodRx Holdings Inc provides digital healthcare platform that provides prescription drugs at affordable prices. The company offers services like diabetes testing, general visits, blood tests, HIV testing, Vitamin D screening, Pregnancy testing, and many more.